← All Invivyd, INC filings

Invivyd, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
IVVD
Invivyd, INC
10-K: Invivyd's 2025 Annual Report: PEMGARDA Sales Up, VYD2311 Advances, Going Concern Doubt Persists
Invivyd, Inc. reports increased PEMGARDA sales and significant clinical progress for VYD2311 in 2025, yet faces substantial doubt about its ability to continue as a going concern due to recurring losses.
NASDAQ
IVVD
Invivyd, INC
10-K: Invivyd's 10-K Filing Reveals Focus on PEMGARDA Commercialization and VYD2311 Development
Invivyd's 10-K filing highlights the company's focus on commercializing PEMGARDA and advancing VYD2311, while navigating financial uncertainties and regulatory landscapes.
NASDAQ
IVVD
Invivyd, INC
10-K: Invivyd, Inc. Details Common Stock and Regulatory Landscape in 10-K Filing
Invivyd, Inc.'s 10-K filing outlines the company's common stock details, regulatory environment, and recent emergency use authorization for PEMGARDA.